EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition

Valentina Fogal, Filippos Michopoulos, Andrew F Jarnuczak, Ghaith M Hamza, Stephanie Harlfinger, Paul Davey, Heather Hulme, Stephen J Atkinson, Piotr Gabrowski, Tony Cheung, Michael Grondine, Clare Hoover und 10 weitere

Archives of Toxicology · 2024

DOI: 10.1007/s00204-024-03771-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Toxicology, 2024. Verfasst von Valentina Fogal und 21 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Safety, Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK. Hauptthemen laut MEDLINE: Methionine Adenosyltransferase, S-Adenosylmethionine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daphne Jackson Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The tumour suppressor p16/CDKN2A and the metabolic gene, methyl-thio-adenosine phosphorylase (MTAP), are frequently co-deleted in some of the most aggressive and currently untreatable cancers. Cells with MTAP deletion are vulnerable to inhibition of the metabolic enzyme, methionine-adenosyl transferase 2A (MAT2A), and the protein arginine methyl transferase (PRMT5). This synthetic lethality has paved the way for the rapid development of drugs targeting the MAT2A/PRMT5 axis. MAT2A and its liver- and pancreas-specific isoform, MAT1A, generate the universal methyl donor S-adenosylmethionine (SAM) from ATP and methionine. Given the pleiotropic role SAM plays in methylation of diverse substrates, characterising the extent of SAM depletion and downstream perturbations following MAT2A/MAT1A inhibition (MATi) is critical for safety assessment. We have assessed in vivo target engagement and the resultant systemic phenotype using multi-omic tools to characterise response to a MAT2A inhibitor (AZ’9567). We observed significant SAM depletion and extensive methionine accumulation in the plasma, liver, brain and heart of treated rats, providing the first assessment of both global SAM depletion and evidence of hepatic MAT1A target engagement. An integrative analysis of multi-omic data from liver tissue identified broad perturbations in pathways covering one-carbon metabolism, trans-sulfuration and lipid metabolism. We infer that these pathway-wide perturbations represent adaptive responses to SAM depletion and confer a risk of oxidative stress, hepatic steatosis and an associated disturbance in plasma and cellular lipid homeostasis. The alterations also explain the dramatic increase in plasma and tissue methionine, which could be used as a safety and PD biomarker going forward to the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methionine AdenosyltransferaseS-AdenosylmethionineAnimalsMaleLiverRatsMethionineRats, Sprague-DawleyPurine-Nucleoside PhosphorylaseProtein-Arginine N-MethyltransferasesMultiomics

Stichwörter der Autor:innen

Drug safetyMAT2A enzymeMetabolomicsMethionine metabolismMulti-omicsOne-carbon metabolism

Substanzen

Methionine AdenosyltransferaseS-AdenosylmethionineMethioninePurine-Nucleoside PhosphorylaseProtein-Arginine N-MethyltransferasesMAT2A protein, human

Autor:innen und Institutionen

  • Oncology Safety, Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
  • Cancer Metabolism & Systems Toxicology Group, Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK.
  • Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.
  • Discovery Biology, Discovery Sciences, R&D, AstraZeneca, R&D Boston, Waltham, USA.
  • DMPK, Oncology R&D, AstraZeneca, Cambridge, UK.

ORCID-Profile: Muireann Coen

Förderung

  • Daphne Jackson Trust

Zitieren

APA

Fogal, V., Michopoulos, F., Jarnuczak, A. F., Hamza, G. M., Harlfinger, S., Davey, P., Hulme, H., Atkinson, S. J., Gabrowski, P., Cheung, T., Grondine, M., Hoover, C., Rose, J., Bray, C., Foster, A. J., Askin, S., Majumder, M. M., Fitzpatrick, P., Miele, E., …, & Coen, M. (2024). Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition. Archives of Toxicology. https://doi.org/10.1007/s00204-024-03771-w

Vancouver

Fogal V, Michopoulos F, Jarnuczak AF, Hamza GM, Harlfinger S, Davey P, et al. Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition. Archives of Toxicology. 2024. doi:10.1007/s00204-024-03771-w

BibTeX
@article{Fogal2024,
  author = {Fogal, Valentina and Michopoulos, Filippos and Jarnuczak, Andrew F and Hamza, Ghaith M and Harlfinger, Stephanie and Davey, Paul and Hulme, Heather and Atkinson, Stephen J and Gabrowski, Piotr and Cheung, Tony and Grondine, Michael and Hoover, Clare and Rose, Jonathan and Bray, Chandler and Foster, Alison J and Askin, Sean and Majumder, Muntasir Mamun and Fitzpatrick, Paul and Miele, Eric and Macdonald, Ruth and Keun, Hector C and Coen, Muireann},
  title = {Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition},
  journal = {Archives of Toxicology},
  year = {2024},
  doi = {10.1007/s00204-024-03771-w}
}
Kostenlos starten →